Unjha Formulations Reports Positive Growth in Q1 FY25 Financial Results

Unjha Formulations, a microcap pharmaceutical company, has recently announced its financial results for the quarter ending June 2024. The company has shown positive growth in its financial performance, with a score of 15 out of 100, an improvement from 9 in the last 3 months.

One of the key factors contributing to this growth is the net sales, which have increased by 26.97% year on year, reaching Rs 8.38 crore in the first half of the year. This indicates a positive sales trend in the near term for the company.

Another positive aspect of Unjha Formulations’ financials is its operating cash flow, which has been the highest in the last three years at Rs 1.03 crore. This shows that the company has generated higher cash revenues from its business operations.

In terms of operating profit, Unjha Formulations has also shown a positive trend, with the highest PBDIT (Profit Before Depreciation, Interest, and Taxes) of Rs 0.72 crore in the last five quarters. Similarly, the company’s PBT (Profit Before Tax) and PAT (Profit After Tax) have also been the highest in the last five quarters, at Rs 0.70 crore each. This indicates a positive trend in the near term for the company’s profitability.

Furthermore, Unjha Formulations has also shown an increase in its earnings per share (EPS), reaching the highest at Rs 1.56 in the last five quarters. This shows that the company has been able to create higher earnings for its shareholders.

Based on these financial results, MarketsMOJO has given a ‘Sell’ call for Unjha Formulations’ stock. However, it is important to note that this is not a recommendation and should not be considered as such. This news article is purely based on the facts and figures provided by the company’s financial report and does not include any external data or sources.